Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens. EULAR has commissioned a task force to study the issue, review the literature and provide perspective and guidance.
Are you a zoomatologist or a doomsatologist? Zoom has replaced the meeting, the teleconference or the board meeting. If your old meetings were bad, then your replacement zoom meetings will also be bad, if not worse. Largely because you have failed to master the medium. Here are the new rules of Zoom.
Dr. John Cush RheumNow
5 years 9 months ago
Broadalumab the other IL-17 inhibitor, is FDA approved for psoriasis. The AMVISION-1 & AMVISION-2 ph III trials in psoriatic arthritis showed in 962 PsA pts it was effective w/ week 16 ACR20 of ~46% (vs 21% PBO). AEs unremarkable w/ 1 case of depression https://t.co/zrsVD7N3Z9
Dr. John Cush RheumNow
5 years 9 months ago
Hello 2021 and new drug price hikes - on average a 4.2% hike in over 500 drugs (past years saw an avg hike ~5%). Increases include Cosentyx 7%, Humira & Rinvoq 7.4%, Orencia 4.5%, Taltz 5%, Actemra 3%, Benlysta 5%, Xeljanz 4.9% & Cimzia 4%
Dr. John Cush RheumNow
5 years 9 months ago
WooHoo. Got my 2nd Covid-19 vax shot. Now my B cells are in overdrive against the nasty COVID. Please get yours. ASAP https://t.co/rRj44GpJxl
Dr. John Cush RheumNow
5 years 9 months ago
Study of 100 pts w/ Granulomatosis with polyangiitis finds 56% had elevated d-dimer levels and that d-dimer are associated with disease activity and inflammation rather than with the risk of venous thromboembolism. 23 had VTE not predicted by d-dimer https://t.co/zIYKXNl0oO
Dr. John Cush RheumNow
5 years 9 months ago
Telemedicine Less Utilized in the South and Urban Areas-- an MMWR student from 7/20 shows that urban health centers were more likely to provide virtual visits that those in rural areas.
https://t.co/DU9HjGXOHQ https://t.co/eBJJXK2qg9
Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.
Amazingly, we made it through 2020, a most forgettable year.
Life was great in the first 3 months of 2020, and then COVID hit the fan and a pandemic steamroller derailed life as we knew it.
Dr. John Cush RheumNow
5 years 9 months ago
Join us this March for RheumNow Live! Sign up via the link below.
https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI
Dr. John Cush RheumNow
5 years 9 months ago
Study of 2050 Northern Italian arthritis clinic pts; where 1.1-1.4% of population developed COVID-19. Steroid use was independently associated with increased COVID risk (adj OR 1.23 to 3.20). But Rx w/ ts/bDMARDs had reduced risk (adj OR 0.46). https://t.co/cLXdpzda9t
Dr. John Cush RheumNow
5 years 9 months ago
Rifampin is safest! 2 RCTs of 6485 latent TB pts compared 9 mos of isoniazid vs 4 mos of rifampicin. RIF had half the adverse events compared to INH; roughly half the rate of rash (1.5% v 2.7%); No grade 3-4 hepatotoxicity w/ RIF, compared 6%) w/ INH https://t.co/6Nz0zeP8ik
Dr. John Cush RheumNow
5 years 9 months ago
MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zJJp8
Dr. John Cush RheumNow
5 years 9 months ago
Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/8IQRHoPqBl https://t.co/5MkvEKcNJg
Dr. John Cush RheumNow
5 years 9 months ago
#Bestof2020
Plaquenil Does Not Protect Lupus Patients from COVID-19
https://t.co/R5S7phlqYb https://t.co/HDlDfE98RQ
